Patent Application
20220347157
(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
There remains a need for novel pharmaceutical compositions comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
Provided is a pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of this disclosure, are intended for purposes of illustration only and are not intended to limit the scope of this disclosure.
The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.
As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, also known as (+)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane, is shown as Formula I below.
“(1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane” and “(+)-1-(naphthalen-2-yl)-3-azabicyclo[3 .1.0]hexane” are used interchangeably herein.
(1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane is an unbalanced triple reuptake inhibitor with the most potency towards norepinephrine reuptake (NE), one-sixth as much towards dopamine reuptake (DA), and one-fourteenth as much towards serotonin reuptake (5-HT).
(1R,5S)-1-(naphtha len-2-yl)-3 -azabicyclo [3.1.0] hexane may be synthesized as described in U.S. Pat. No. 8,461,196 or International Publication No. WO 2013/019271, both of which are incorporated herein by reference in their entirety.
As used herein, “substantially free of the corresponding (—) enantiomer” means more of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane than the corresponding (—) enantiomer, i.e., (1S ,5R)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0] hexane. In some embodiments, “substantially free of the corresponding (—) enantiomer” means containing no more than 20% w/w (weight/weight) of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 10% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 5% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 2% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form, e.g., no more than 1% w/w of the corresponding (—) enantiomer, in free or pharmaceutically acceptable salt form.
As used herein, “(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane” embraces the compound in any form, for example, free or pharmaceutically acceptable salt form, e.g., as a pharmaceutically acceptable acid addition salt. Pharmaceutically acceptable salts are known in the art and include salts that are physiologically acceptable at the dosage amount and form to be administered, for example, hydrochloride salts.
As used herein, “(1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0]hexane” is also to be understood as embracing the compound in crystalline and amorphous form including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof. “Crystalline form” and “polymorph” may be used interchangeably herein, and are meant to include all crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, including, for example, polymorphs, solvates (including hydrates), unsolvated polymorphs (including anhydrates), and conformational polymorphs, as well as mixtures thereof, unless a particular crystalline form is referred to.
Crystalline and amorphous forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may be used in any combination or in forms that are substantially free of one or more of the other crystalline forms or free of the amorphous form.
(1R, 5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane may in some cases also exist in prodrug form. Prodrugs are considered to be any covalently bonded carriers that release the active parent drug in vivo.
As used herein, “concurrently” means the compounds are administered simultaneously or within the same composition. In some embodiments, the compounds are administered simultaneously. In some embodiments, the compounds are administered within the same composition.
The nominal viscosity of polymers, e.g., hydroxypropyl methylcellulose may be measured, for example, at a 2% concentration in water at 20° C. according to the U.S. Pharmacopeia and by other techniques known to those skilled in the art.
Particle size measurements may be made, for example, by laser diffraction and by other techniques known to those skilled in the art.
In some embodiments, the pharmaceutical compositions disclosed herein comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, including by sustained release, although various other known delivery routes, devices and methods can likewise be employed. In some embodiments, provided is a sustained release pharmaceutical composition, e.g., an oral sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, which provides therapeutically effective levels of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane over a sustained delivery period of approximately 6 hours or longer, e.g., 8 hours or longer, e.g., 12 hours or longer, e.g., 18 hours or longer, e.g., 24 hours or longer.
In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that from about 0% to 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 0 to 2 hours, from 20% to 50% of the active compound is released and delivered within about 2 to 12 hours, from 50% to 85% of the active compound is released and delivered within about 3 to 20 hours, and greater than 75% of the active compound is released and delivered within about 5 to 18 hours.
In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 20% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 4 or less hours after administration, e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 40-60% is released and delivered within 4 hours or less after administration.
In some embodiments, (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, is released from a pharmaceutical composition as disclosed herein and delivered into the blood plasma or other target site of activity in the subject (including, but not limited to, areas of the brain such as the prefrontal cortex, frontal cortex, thalamus, striatum, ventral tegmental area, other cortical areas, hippocampus, hypothalamus, or nucleus accumbens) in a sustained release profile characterized in that at least 50% of the active compound is released and delivered (as determined, e.g., by measuring blood plasma levels) within 8 hours or less after administration, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is released and delivered within 8 hours or less after administration.
In some embodiments, at least 20% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, e.g., at least about 30%, e.g., at least about 40%, e.g., about 20-80%, e.g., about 30-70%, e.g., about 30-60%, e.g., about 40-60%, e.g., about 50-60%, e.g., about 50%, e.g., about 60%, is released and dissolved within 4 hours or less (e.g., within about 2-4 hours, e.g., about within 3-4 hours, e.g., about 4 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and at 37° C.±0.5. In addition, in some embodiments, at least 50% of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, e.g., at least about 60%, e.g., at least about 70%, e.g., at least about 80%, e.g., about 50-90%, e.g., about 60-90%, e.g., about 60-80% is released and dissolved within 8 hours or less (e.g., within about 6-8 hours, e.g., within about 7-8 hours, e.g., about 8 hours) from a pharmaceutical composition as disclosed herein as measured in 900 mL water using USP Apparatus 2 paddle, at 50 rpm and 37° C.±0.5.
In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 80%, e.g., less than about 75%, e.g., less than about 60%, e.g., less than about 50%, e.g., less than about 40%, e.g., less than about 30% of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition. In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-y1)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-80%, e.g., is about 30-80%, e.g., is about 20-70% e.g., is about 30-70%, e.g., is about 30-60%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
(1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphth alen-2-yl)-3- azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is less than about 50%, e.g., less than about 40%, e.g., less than about 30%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition. In some embodiments, the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0] hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0] hexane, in free or pharmaceutically acceptable salt form, as disclosed herein is about 20-50%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3 -azabicyclo [3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
In some embodiments, the pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, e.g., a sustained release pharmaceutical composition, comprises a lubricant, e.g., magnesium stearate, a carrier, e.g., lactose monohydrate, or a combination thereof.
Provided is a pharmaceutical composition (Composition 1), e.g., a sustained release pharmaceutical composition, comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
Further provided is Composition 1 as follows:
1.1 Composition 1 wherein the composition is sustained release.
1.2 Composition 1 or 1.1 wherein the pharmaceutical composition is substantially free of the corresponding (—) enantiomer.
1.3 Composition 1, 1.1, or 1.2 wherein the composition comprises less than or equal to 20% w/w of the corresponding (—) enantiomer.
1.4 Any of Compositions 1 or 1.1-1.3 wherein the composition comprises less than or equal to 10% w/w of the corresponding (—) enantiomer.
1.5 Any of Compositions 1 or 1.1-1.4 wherein the composition comprises less than or equal to 5% w/w of the corresponding (—) enantiomer.
1.6 Any of Compositions 1 or 1.1-1.5 wherein the composition comprises less than or equal to 2% w/w of the corresponding (—) enantiomer.
1.7 Any of Composition 1 or 1.1-1.6 wherein the composition comprises less than or equal to 1% w/w of the corresponding (—) enantiomer.
1.8 Any of Compositions 1 or 1.1-1.7 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is in pharmaceutically acceptable salt form.
1.9 Composition 1.8 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is an acid addition salt.
1.10 Composition 1.9 wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride.
1.11 Any of Compositions 1 or 1.1-1.10 comprising 1 mg to 1800 mg, e.g., 10 mg to 1800 mg, e.g., 25 mg to 1800 mg, e.g., 10 mg to 1600 mg, e.g., 10 mg to 1200 mg, e.g., 50 mg to 1200 mg, e.g., 50 mg to 1000 mg, e.g., 75 mg to 1000 mg, e.g., 75 mg to 800 mg, e.g., 75 mg to 500 mg, e.g., 100 mg to 750 mg, e.g., 100 mg to 500 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 300 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.12 Any of Compositions 1 or 1.1-1.11 comprising 75 mg to 1000 mg, e.g., 100 mg to 600 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.13 Any of Compositions 1 or 1.1-1.11 comprising 50 mg to 600 mg, e.g., 100 mg to 600 mg, e.g., 100 mg to 400 mg, e.g., 100 mg to 200 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.14 Any of Compositions 1 or 1.1-1.11 comprising 5 mg to 500 mg, e.g., 5 mg to 10 mg, e.g, 10 mg to 25 mg, e.g., 30 mg to 50 mg, e.g., 10 mg to 300 mg, e.g., 25 mg to 300 mg, e.g., 50 mg to 100 mg, e.g., 100 mg to 250 mg, e.g., 250 mg to 500 mg, of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.15 Any of Compositions 1 or 1.1-1.10 for administration of 0.5 mg/kg to 20 mg/kg per day, e.g., 1 mg/kg to 15 mg/kg per day, e.g., 1 mg/kg to 10 mg/kg per day, e.g., 2 mg/kg to 20 mg/kg per day, e.g., 2 mg/kg to 10 mg/kg per day, e.g., 3 mg/kg to 15 mg/kg per day, of (1R,5 S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
1.16 Any of Compositions 1 or 1.1-1.15 comprising less than 50% w/w of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, e.g., less than about 40% w/w, e.g., less than about 30% w/w, less than about 20% w/w, e.g., about 1-40% w/w, e.g., about 5-40% w/w, e.g., about 10-30% w/w, e.g., about 15-25% w/w, e.g., about 15-20% w/w, e.g., about 17% w/w, e.g., about 25% w/w. 1.17 Any of Compositions 1 or 1.1-1.16 further comprising hydroxypropyl methylcellulose (e.g., hypromellose HPMC K4M).
1.18 Composition 1.17 wherein the composition comprises at least 10% w/w of the hydroxypropyl methylcellulose, e.g., about 10-50% w/w, e.g., about 10-40% w/w, e.g., about 20-50% w/w, e.g., about 20-40% w/w, e.g., about 30-40% w/w, e.g., about 37% w/w.
1.19 Composition 1.17 or 1.18 wherein the degree of methoxy substitution of the hydroxypropyl methylcellulose is 19-24%.
1.20 Any of Compositions 1.17-1.19 wherein the degree of hydroxypropoxy substitution of the hydroxypropyl methylcellulose is 4-12%.
1.21 Any of Compositions 1.17-1.20 wherein the hydroxypropyl methylcellulose is hypromellose 2208.
1.22 Any of Compositions 1.17-1.21 wherein the hydroxypropyl methylcellulose has a nominal viscosity of 4,000 mPA·s.
1.23 Any of Compositions 1.17-1.21 wherein the hydroxypropyl methylcellulose has a viscosity of 2,000-6,000 mPA·s, e.g., about 2,600 to 5,000 mPA·s, e.g., about 2,663 to 4,970 mPA·s.
1.24 Any of Compositions 1 or 1.1-1.23 wherein the composition further comprises lactose (e.g., alpha-lactose monohydrate).
1.25 Composition 1.24 wherein the composition comprises at least 10% w/w of the alpha-lactose monohydrate, e.g., about 10-80% w/w, e.g., about 20-70% w/w, e.g., about 20-60% w/w, e.g., about 20-50% w/w, e.g., about 20-40% w/w, e.g., about 20-30% w/w, e.g., about 30-70% w/w, e.g., about 30-60% w/w, e.g., about 30-50% w/w, e.g., about 30%-40% w/w, e.g., about 37% w/w.
1.26 Composition 1.24 or 1.25 wherein the composition comprises milled alpha-lactose monohydrate.
1.27 Any of Compositions 1 or 1.1-1.26 wherein the composition comprises a co-processed mixture of hydroxpropyl methylcellulose and alpha-lactose monohydrate (e.g., Retalae).
1.28 Composition 1.27 wherein the mixture comprises equal parts of the hydroxpropyl methylcellulose and alpha-lactose monohydrate.
1.29 Composition 1.27 or 1.28 wherein the mixture comprises particles of hydroxpropyl methylcellulose and alpha-lactose monohydrate with d50 (median diameter) in the range of 100 to 200 gym, e.g., about 125
1.30 Any of Compositions 1.27-1.29 wherein the mixture comprises particles of hydroxpropyl methylcellulose and alpha-lactose monohydrate wherein the particle size distribution is as follows:
Polyplasdone XL-10) and sodium starch glycolate (e.g., Explotab).
1.39 Composition 1.36 wherein the binder is polyvinylpyrrolidone (e.g., Povidone K29/32).
1.40 Composition 1.36 wherein the modified release agent is one or more of hydroxypropyl cellulose (e.g., Klucel EXF, Klucel MXF and/or Klucel HXF) and hydroxypropyl methylcellulose (e.g., Methocel K100M, Methocel K4M PREM, Methocel K15M PREM CR).
1.41 Composition 1.36 or 1.40 wherein the composition comprises at least 5% w/w of the modified release agent, e.g., about 5-60% w/w, e.g., about 10-50% w/w, e.g., about 10-40% w/w.
1.42 Composition 1.40 or 1.41 wherein the modified release agent is hydroxypropyl methylcellulose.
1.43 Composition 1.42 wherein the degree of methoxy substitution of the hydroxypropyl methylcellulose is 19-24%.
1.44 Composition 1.42 or 1.43 wherein the degree of hydroxypropoxy substitution of the hydroxypropyl methylcellulose is 4-12%.
1.45 Any of Compositions 1.42-1.44 wherein the hydroxypropyl methylcellulose is hypromellose 2208.
1.46 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 75,000-140,000 mPA·s.
1.47 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 2,000-6,000 mPAs, e.g., about 2,600 to 5,000 mPAs, e.g., about 2,663 to 4,970 mPA·s.
1.48 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 12,000-26,000 mPAs, e.g., about 13,000 to 25,000 mPA·s, e.g., about 13,275 to 24,780 mPA·s.
1.49 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 100,000 cps.
1.50 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 3,600 cps.
1.51 Any of Compositions 1.42-1.45 wherein the hydroxypropyl methylcellulose has a viscosity of 18,000 cps.
1.52 Composition 1.36, 1.40, or 1.41 wherein the modified release agent is hydroxypropyl cellulose (e.g., Klucel EXF, Klucel MXF and/or Klucel HXF).
1.53 Any of Compositions 1 or 1.1-1.52 for administration once, twice, three, or four times daily.
1.54 Any of Compositions 1 or 1.1-1.53 further comprising another drug.
1.55 Any of Compositions 1 or 1.1-1.54 wherein the composition further comprises an mG1uR1 antagonist, an mGluR2/3 antagonist, an mGluR5 antagonist, an AMPA receptor positive modulator, an NMDA receptor antagonist, a tetracycline antibiotic, an α2-adrenergic agonist, an antipsychotic, an anti-depressant (e.g., a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), or a tricyclic anti-depressant), a benzodiazepine, an anti-convulsant, a mood stabilizer, a gamma-aminobutyric acid (GABA) agonist e.g., a GABA-B agonist, a GABA modulator, a stimulant, a β-blocker, a hormone, or a combination thereof.
1.56 Any of Compositions 1 or 1.1-1.55 wherein the composition further comprises fenobam, mavoglurant (AFQ056), dipraglurant, R04917523, STX107, 2-methyl-6-phenylethynyl pyridine (MPEP), CX516, memantine, acamprosate, minocycline, clonidine, guanfacine, aripiprazole, risperidone, citalopram, escitalopram, fluoxetine, sertraline, fluovoxamine, paroxetine, trazodone, bupropion, imipramine, amitriptyline, venlafaxine, nefazodone, duloxetine, venlafaxine, carbamazepine, lamotrigine, valproic acid, sodium valproatc, lithium, quctiapinc, folic acid, L-acctylcarnitinc, mclatonin, arbaclofcn, doncpczil hydrochloride, alpha-tocopherol, methylphenidate, amphetamine mixed salts (e.g., Adderall), dextroamphetamine, risperidone, olanzapine, ziprasidone, buspirone, filuzole, metadoxine, primidone, topiramate, estradiol, cyclic medroxyprogesterone, or a combination thereof.
1.57 Any of Compositions 1 or 1.1-1.56 further comprising an mGluR5 antagonist.
1.58 Composition 1.57 further comprising fenobam, mavoglurant (AFQ056), dipraglurant, RO4917523, STX107, 2-methyl-6-phenylethynyl pyridine (MPEP), or a combination thereof
1.59 Composition 1.58 further comprising RO4917523, mavoglurant (AFQ056), or a combination thereof.
1.60 Any of Compositions 1 or 1.1-1.59 further comprising a GABA-B agonist.
1.61 Composition 1.60 comprising arbaclofen.
1.62 Any of Compositions 1 or 1.1-1.61 further comprising a GABA modulator.
1.63 Composition 1.62 further comprising acamprosate.
1.64 Any of Compositions 1 or 1.1-1.63 further comprising minocycline.
1.65 Any of Compositions 1 or 1.1-1.64 wherein the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of the composition is less than about 80%, e.g., less than about 75%, e.g., less than about 60%, e.g., less than about 50%, e.g., less than about 40%, e.g., less than about 30%, e.g., is about 20-80%, e.g., is about 30-80%, e.g., is about 20-70% e.g., is about 30-70%, e.g., is about 30-60%, e.g., is about 30-50%, e.g., is about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
1.66 Any of Compositions 1 or 1.1-1.65 wherein the Cmax of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, provided after administration of a sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is less than about 50%, e.g., less than about 40%, e.g., less than about 30%, e.g., about 20-50%, e.g., about 30-50%, e.g., about 30-40%, of the Cmax obtained after administering an equivalent dose of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexane, in free or pharmaceutically acceptable salt form, in an immediate release pharmaceutical composition.
1.67 Composition 1 wherein the composition comprises 25% w/w (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, 74.5% w/w of an equal parts mixture of hydroxypropyl methylcellulose and alpha-lactose monohydrate, and 0.5% w/w magnesium stearate.
1.68 Any of Compositions 1 or 1.1-1.67 for use in indications as described in U.S. Pat. No. 8,461,196, International Publication No. WO 2013/019271, and International Patent Application No. PCT/US14/69401, the contents of each of which are hereby incorporated by reference.
Sustained release pharmaceutical compositions comprising (1R,5S)-1 -(naphthalen-2-yl)-3-azabicyclo [3.1.0]hexanehydrochloride may be made utilizing a direct blend process, with screening of the excipients and (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride through a Quadro 197S Co-Mil, and blending in a V-shell blender prior to compression on a rotary tablet press.
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
HPLC conditions for dissolution and dissolution conditions for Examples 3-9 are set forth in Tables 1 and 2.
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8kp±2 kp.
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8kp±2 kp.
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Manufacture by a direct blend process. Compress on Dynamic Exim rotary tablet press using concave ⅜″ tooling. Compress at a target weight of 300 mg (±15 mg) and target hardness of approximately 8 kp±2 kp.
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Sustained release pharmaceutical composition comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride
Batch has an approximate 50% dissolution release at 4 hours and approximate 80% release at 8 hours.
| Number | Date | Country | |
|---|---|---|---|
| 61913886 | Dec 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17443763 | Jul 2021 | US |
| Child | 17691911 | US | |
| Parent | 15102949 | Jun 2016 | US |
| Child | 17443763 | US |
